LONGTERM CARDIOVASCULAR OUTCOME AFTER BARE-METAL STENTING POST-DILATED WITH THE PACLITAXEL-ELUTING BALLOON IS NON-INFERIOR COMPARED TO THE XIENCE V DRUG-ELUTING STENT: 2-YEAR CLINICAL DATA FROM THE OCTOPUS TRIAL

We aimed to investigate bare metal stents (BMS) post-dilated with paclitaxel-eluting balloons (DEB) and hypothesized sufficient stent coverage after 6 months and prevention of target-lesion restenosis (TLR). In this randomized trial ([NCT01056744][1]) 105 lesions in 90 patients were randomly